Thomas E. Hutson, D.O., Pharm.D., FACP, is the director of the Urologic Oncology Program and Co-Chair of the Urologic Cancer Research and Treatment Center at Baylor University Medical Center; and is a Professor of Medicine at Texas A&M College of Medicine. Dr. Hutson is recognized internationally as a leader in the field of urologic cancers; has authored over 500 scholarly works; is regularly invited to speak at medical venues around the world; and is the clinical lead investigator on several international research trials.
Dr. Hutson received his bachelor’s and doctor of pharmacy degrees from Ohio Northern University and his doctor of osteopathic medicine degree from Ohio University. He completed his residency in internal medicine, followed by fellowships in medical oncology and experimental therapeutics at the Cleveland Clinic.
Faith, and the relationship between religion and medicine, has been of particular importance to Dr. Hutson, especially in the area of end of life care. He has served as the medical director for Holy Savior Hospice in Dallas, Texas, and is an active member of the Christian Medical Dental Association. He is currently enrolled in theological studies at Dallas Theological Seminary and Southern Baptist Theological Seminary.
Accolades & Memberships:
Thomas is married to Kimberly Hodges Hutson. The couple and their two sons reside in Plano, Texas.
Current optimal chemotherapy for advanced urothelial cancer.
Expert Review of Anticancer Therapy, 2008
A novel multitargeted tyrosine kinase inhibitor.
Current Oncology Report, 2007
Management of recurrent testicular germ cell tumors.
Neoadjuvant therapy followed by prostatectomy for clinically localized prostate cancer.
Novel agents for urothelial cancer: review
British Journal of Urology International, 2007
Phase I trial of PEG-Intron and rIL-2 in patients with metastatic renal cell carcinoma
Cancer Chemotherapy and Pharmacology, 2007
Phase II trial of capecitabine and rHU-interferon-alpha-2a in patients with metastatic renal cell carcinoma, limited efficacy and moderate toxicity.
Urology Oncology, 2007
Phase III randomized trial of sunitinib malate versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma.
New England Journal of Medicine, 2007
Recent advances in the therapy of renal cancer.
Expert Opinion on Biological Therapy, 2007
Renal Cell Carcinoma: Recent Advances.
The Cancer Journal
Safety and tolerability of sorafenib in clear-cell renal cell carcinoma – a phase III overview.
Expert Review of Anticavity Therapy, 2007
Targeted therapy for renal cell carcinoma: A new treatment paradigm
Baylor Health Care Center Proceedings, 2007
The evolving role of novel targeted agents in renal cell carcinoma.
Treatment Approaches in Renal cancer Global Evaluation Trial (TARGETs)
New England Journal of Medicine
A phase II study of GW786034 using a randomized discontinuation design in patients with locally recurrent or metastatic clear-cell renal cell carcinoma.
Clinical Genitourinary Cancer
Phase I trial of phenoxodiol delivered by continuous intravenous infusion.
Annals of Oncology, 2006
Problems with randomized discontinuation design.
Journal of Clinical Oncology, 2006
Systemic Chemotherapy for Urothelial Cancer.
Clinical Genitourinary Cancer, 2006
Treatment of Patients with Metastatic Renal Cell Carcinoma: A RAND appropriateness panel